ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 98.99M | 84.28M | 142.77M | 112.34M | 97.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.99M | 84.28M | 142.77M | 112.34M | 97.12M |
| Cost of Revenue | 40.18M | 33.60M | 27.90M | 21.49M | 19.37M |
| Gross Profit | 58.81M | 50.67M | 114.87M | 90.85M | 77.75M |
| SG&A Expenses | 261.22M | 230.12M | 205.66M | 150.19M | 104.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 301.40M | 263.73M | 233.56M | 171.68M | 124.19M |
| Operating Income | -202.42M | -179.45M | -90.79M | -59.34M | -27.07M |
| Income Before Tax | -198.06M | -171.38M | -79.75M | -47.73M | -15.36M |
| Income Tax Expenses | -80.00K | -80.00K | 288.00K | 288.00K | 288.00K |
| Earnings from Continuing Operations | -197.98 | -171.30 | -80.04 | -48.02 | -15.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -197.98M | -171.30M | -80.04M | -48.02M | -15.65M |
| EBIT | -202.42M | -179.45M | -90.79M | -59.34M | -27.07M |
| EBITDA | -200.93M | -178.08M | -89.81M | -58.73M | -26.72M |
| EPS Basic | -2.00 | -1.74 | -0.81 | -0.49 | -0.16 |
| Normalized Basic EPS | -1.22 | -1.06 | -0.47 | -0.27 | -0.06 |
| EPS Diluted | -2.00 | -1.74 | -0.90 | -0.58 | -0.25 |
| Normalized Diluted EPS | -1.22 | -1.06 | -0.53 | -0.33 | -0.13 |
| Average Basic Shares Outstanding | 395.49M | 394.26M | 392.63M | 390.85M | 389.32M |
| Average Diluted Shares Outstanding | 395.49M | 394.26M | 414.44M | 412.67M | 411.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |